Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study

Documenti analoghi

• SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
  di: Saad, Farid, et al.
  Pubblicazione: (2019)
• SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
  di: Haider, Karim, et al.
  Pubblicazione: (2019)
• SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
  di: Saad, Farid, et al.
  Pubblicazione: (2019)
• OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
  di: Haider, Ahmad, et al.
  Pubblicazione: (2019)
• Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups
  di: Traish, Abdulmaged M., et al.
  Pubblicazione: (2017)